 The Star-Ledger – NJ.com |
NJ's Merck forges partnership to develop new medicines for asthma and other …
The Star-Ledger – NJ.com Lycera is working on drug candidates that target two pathways, so called Th17 cells and RORyt, that play a critical role in immune-mediated diseases, including psoriasis, asthma and inflammatory bowel disease. Merck, which is based in Whitehouse … Merck and Lycera to Develop Oral Autoimmune Disease Drugs Targeting Th17 Cells |
View full post on asthma – Google News